Displaying 2681 - 2700 of 4742
Medtronic, Inc. and Covidien plc, In the Matter of
Global medical technology company Medtronic, Inc. agreed to divest the drug-coated balloon catheter business of Ireland-based medical products company Covidien plc, in order to settle FTC charges that its $42.9 billion acquisition of Covidien would likely be anticompetitive. Under the FTC’s proposed settlement, Medtronic will sell the drug-coated balloon catheter business to a Colorado-based medical device company, The Spectranetics Corporation. According to the FTC’s complaint, both Medtronic and Covidien are developing drug-coated balloon catheters to compete with C.R. Bard, Inc., which currently is the only company that supplies these products, used to treat peripheral artery disease, in the U.S. market. Medtronic and Covidien are the only companies with products in clinical trials in the Food and Drug Administration’s approval process, which makes it unlikely that other competitors could enter the market in time to counteract the effects of the merger.
FTC Approves Final Order Preserving Competition in the Market for Nicotine Patches
1501002 Informal Interpretation
FTC Announces New Thresholds for Clayton Act Antitrust Reviews for 2015
FTC Approves Modified Final Order for Bi-Lo
Bi-Lo Holdings, LLC, In the Matter of
According to the FTC's complaint, Bi-Lo’s proposed $265 million acquisition of the Delhaize supermarkets would likely harm consumers through higher grocery prices, diminished quality and reduced service levels in 11 local markets in three states. The consent order requires the merged Bi-Lo/Delhaize to sell 12 stores to Rowes IGA Supermarkets, HAC, Inc., W. Lee Flowers & Co., Inc. and Food Giant. Under the terms of the purchase agreement, Bi-Lo will acquire the Delhaize stores on a rolling basis, through eight separate deal closings over a 10-week period. Each supermarket divestiture must be completed within 10 days of the respective Bi-Lo/Delhaize closing date. The FTC settlement preserves supermarket competition in 11 local markets in three states.
FTC Proposes to Study Merger Remedies
FTC Approves Final Order Barring Blue Rhino, AmeriGas from Restraining Competition
AmeriGas and Blue Rhino, In the Matter of
The FTC issued an administrative complaint against Ferrellgas Partners, L.P and Ferrellgas, L.P. (doing business as Blue Rhino) and UGI Corporation and AmeriGas Partners, L.P. (doing business as AmeriGas Cylinder Exchange), alleging that they illegally agreed on reducing the amount of propane in their tanks sold to a key customer. The complaint alleges that, together, Blue Rhino and AmeriGas controlled approximately 80 percent of the market for wholesale propane exchange tanks in the United States. In 2008, Blue Rhino and AmeriGas each decided to implement a price increase by reducing the amount of propane in their exchange tanks from 17 pounds to 15 pounds, without a corresponding reduction in the wholesale price. On 10/31/14, AmeriGas and Blue Rhino agreed to settle FTC charges of restraining competition. Faced with resistance from Walmart, the two companies colluded by secretly agreeing to coordinate their negotiations with Walmart in order to push it to accept the reduction. The consent agreements prohibit the companies from soliciting, offering, participating in, or entering or attempting to enter into any type of agreement with any competitor in the propane exchange business to raise, fix, maintain, or stabilize the prices or price levels of propane exchange tanks through any means – including modifying the fill level contained in propane tanks or coordinating communications to customers. The companies also are prohibited from sharing sensitive non-public business information with competitors except in narrowly defined circumstances.
1501001 Informal Interpretation
1412010 Informal Interpretation
1412009 Informal Interpretation
FTC Requests Public Comment on Merck & Co., Inc.’s Application to Approve Sale of Facilities for Manufacturing Heartgard and Heartgard Plus Heartworm Treatments for Dogs
To Settle FTC Charges, Two Trade Associations Agree to Eliminate Rules that Restrict Competition
FTC Staff Issues FY 2013 Report on Branded Drug Firms’ Patent Settlements with Generic Competitors
FTC Puts Conditions on Eli Lilly’s Proposed Acquisition of Novartis Animal Health
Displaying 2681 - 2700 of 4742